Inhibitor Therapeutics, Inc. Accrued Liabilities, Current
Inhibitor Therapeutics, Inc. (INTI) had Accrued Liabilities, Current of $9.58 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $9.58K.
- 2026-03-31: Accrued Liabilities, Current $33.54K.
- 2025-12-31: Accrued Liabilities, Current $690.09K.
- 2025-09-30: Accrued Liabilities, Current $40.43K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $9.58K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $33.54K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $690.09K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $40.43K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $7.72K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $32.02K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $693.72K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $42.85K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $16.72K 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $43.93K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $631.43K 10-K · filed 2025-03-28 | |
| 2023-09-30 | $63.29K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $32.11K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $73.44K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $122.62K 10-K · filed 2024-03-29 | |
| 2021-12-31 | $53.00K 10-K · filed 2023-03-31 | |
| 2015-06-30 | $103.00K 10-Q · filed 2015-08-14 | |
| 2014-12-31 | $23.00K 10-Q · filed 2015-08-14 | $73.18K 10-K · filed 2015-02-13 |